It has been postulated that enhancing insulin-receptor signaling in these areas, using certain antidiabetic agents such as insulin, thiazolidinediones, and glucagon-like peptide-1 (GLP-1) receptor agonists, may offer therapeutic benefits to individuals with AD [17]. This evidence concerns the gene INSR and Alzheimer disease.